论文部分内容阅读
目的:探讨TROP2在不同卵巢组织中的表达及其与卵巢浆液性囊腺癌患者临床病理因素之间的关系,明确TROP2表达是否与卵巢浆液性囊腺癌患者预后有关。方法:应用免疫组化法检测TROP2在98例卵巢浆液性囊腺癌组织及50例正常卵巢组织中的表达情况,分析TROP2表达与卵巢浆液性囊腺癌患者临床病理特征的关系,采用COX比例风险回归模型分析影响卵巢浆液性囊腺癌患者预后的因素。结果:TROP2在卵巢浆液性囊腺癌、正常卵巢组织中的表达阳性率分别为55.1%及24.0%,差异有统计学意义(P<0.05)。TROP2表达与卵巢浆液性囊腺癌患者年龄无显著相关(P>0.05),而与患者有无淋巴结转移,组织学分级和临床分期有显著相关(P<0.05);临床分期、病理组织学分级、术后残余灶大小、TROP2基因表达均为影响卵巢浆液性囊腺癌患者预后的危险因素(P<0.05)。结论:TROP2可能成为卵巢浆液性囊腺癌患者治疗的新靶点。
Objective: To investigate the expression of TROP2 in different ovarian tissues and its relationship with clinicopathological factors in patients with ovarian serous cystadenocarcinoma. To determine whether TROP2 expression is associated with the prognosis of patients with ovarian serous cystadenocarcinoma. Methods: The expression of TROP2 was detected in 98 cases of ovarian serous cystadenocarcinoma and 50 cases of normal ovarian tissue by immunohistochemistry. The relationship between TROP2 expression and clinicopathological features of ovarian serous cystadenocarcinoma was analyzed. The proportion of COX Risk Regression Model Analysis of Factors Influencing Prognosis in Patients with Ovarian Serous. Results: The positive rates of TROP2 in ovarian serous cystadenocarcinoma and normal ovarian tissue were 55.1% and 24.0%, respectively, with statistical significance (P <0.05). There was no significant correlation between the expression of TROP2 and the age of ovarian serous cystadenocarcinoma (P> 0.05), but there was a significant correlation between TROP2 expression and lymph node metastasis, histological grade and clinical stage (P <0.05). The clinical stage, pathological grade , Residual size of tumor and TROP2 gene expression were risk factors influencing the prognosis of patients with ovarian serous cystadenocarcinoma (P <0.05). Conclusion: TROP2 may be a new therapeutic target for patients with ovarian serous cystadenocarcinoma.